ALLMedicine™ Hyperglucagonemia Center
Research & Reviews 100 results
https://doi.org/10.2337/db22-0079
Diabetes James H, Gonsalves WI et. al.
May 28th, 2022 - Transient insulin deprivation with concurrent hyperglucagonemia is a catabolic state that can occur in type 1 diabetes. To evaluate glucagon's catabolic effect in the setting of its glucogenic effect, we measured the regional exchanges of amino-me...
https://clinicaltrials.gov/ct2/show/NCT04907721
May 18th, 2022 - Amino acids administered orally or intravenously stimulate glucagon secretion from the pancreas and in turn, glucagon is a powerful stimulus for hepatic amino acid turnover through transcriptional (long-term) and non- transcriptional (acute) mecha...
https://doi.org/10.1016/j.metabol.2022.155199
Metabolism: Clinical and Experimental; Salehi M, Gastaldelli A et. al.
Apr 8th, 2022 - Roux-en Y gastric bypass surgery (GB) and sleeve gastrectomy (SG) alter prandial glucose metabolism, producing lower nadir glucose values and predisposing susceptible individuals to prandial hypoglycemia. The glycemic phenotype of GB or SG is asso...
https://clinicaltrials.gov/ct2/show/NCT04079881
Mar 2nd, 2022 - Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9 years, the absence ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113783
The Journal of Clinical Endocrinology and Metabolism; Stinson SE, Jonsson AE et. al.
Feb 26th, 2022 - In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. The role of glucagon in pediatric overweight/obesity remains unclear. We examined whether fasting concentrations of glucagon are elevated in ...
Clinicaltrials.gov 18 results
https://clinicaltrials.gov/ct2/show/NCT04907721
May 18th, 2022 - Amino acids administered orally or intravenously stimulate glucagon secretion from the pancreas and in turn, glucagon is a powerful stimulus for hepatic amino acid turnover through transcriptional (long-term) and non- transcriptional (acute) mecha...
https://clinicaltrials.gov/ct2/show/NCT04079881
Mar 2nd, 2022 - Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9 years, the absence ...
https://clinicaltrials.gov/ct2/show/NCT03019510
Oct 21st, 2021 - In individuals with type 2 diabetes (T2D), chronically elevated glucose and insulin levels result in numerous health complications. Maintaining tight glucose control is difficult for individuals with T2D, particularly in the postprandial period an...
https://clinicaltrials.gov/ct2/show/NCT04042142
Sep 9th, 2021 - The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Moreover, they propose a dys-coordinated, reduced glucagon se...
https://clinicaltrials.gov/ct2/show/NCT04859322
Apr 30th, 2021 - Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia. This contributes to the hyperglycaemic state of the patients and is considered an important c...
News 4 results
https://www.medpagetoday.com/rheumatology/lupus/64321
Apr 4th, 2017 - Lupus patients had a bi-hormone metabolic abnormality characterized by increased insulin resistance and glucagon levels, despite normal glucose tolerance, according to a Brazilian study. When compared with a control group, patients with systemic l...
https://www.mdedge.com/endocrinology/article/53198/diabetes/glucagon-receptor-blockers-eyed-type-2
Miriam E. Tucker
Oct 1st, 2011 - LISBON – New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes, but only if safety can be established, according to two presentations at.
https://www.mdedge.com/internalmedicine/article/40654/endocrinology/investigational-glucagon-antagonists-show-promise
Miriam E. Tucker
Sep 16th, 2011 - LISBON – New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes, but only if safety can be established, according to two presentations at.
https://www.medscape.com/viewarticle/850125
Abstract and Introduction Abstract Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in ...